CDX0159-02
81 evidence topics · 12 sources
Objective
Primary objective: safety of multiple doses
“The main objective of the trial was to evaluate the barzolvolimab MAD safety profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Primary and secondary objectives were safety and disease activity (UAS7 and urticaria control test [UCT]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary objectives: pharmacokinetics, disease activity, tryptase, SCF, and immunogenicity
“The secondary objectives were to characterize the barzolvolimab MAD PK profile; PD effect (UAS7, HSS7, itch severity score [ISS7], and urticaria control test [UCT]); tryptase and SCF levels; and immunogenicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry purpose: safety, pharmacodynamics, and pharmacokinetics in antihistamine-refractory CSU
Location and study date
Registry dates and study sites in the United States and Germany
| Field | Quoted record |
|---|---|
| Study start (actual) | “2020-09-24” |
| Primary completion (actual) | “2023-01-17” |
| Study completion (actual) | “2023-01-17” |
| Countries of listed sites | “United States”; “Germany” |
| Site in Germany | “Charite University” |
First participant dosed, October 2020
Study completion reported in June 2023
Study design
Randomized, double-blind, placebo-controlled design with screening, treatment, and follow-up periods
“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included the following periods: 2‐week screening, 12‐week treatment, and 12‐week posttreatment follow‐up (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Four sequentially enrolled intravenous cohorts randomized 4:1
Registry title: phase 1 multiple ascending dose add-on study
Dose and schedule selection from the single-dose healthy-volunteer study
“Doses were selected based on results from the single‐dose healthy‐volunteer study [10], in which 0.3–9 mg/kg barzolvolimab was well tolerated and demonstrated dose‐dependent suppression of serum tryptase (Supporting Information Methods).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the sustained tryptase suppression and prolonged serum half‐life observed in the single‐dose study, two dose schedules were evaluated: once every 4 weeks (Q4W) and every 8 weeks (Q8W).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor role in design, data analysis, and manuscript preparation
“This trial was designed and sponsored by Celldex Therapeutics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data were collected by the trial investigators according to Good Clinical Practice guidelines and were analyzed by the sponsor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The first draft of the manuscript was written by a medical writer paid by the sponsor, with critical input and approval from all authors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria: age, disease activity, disease duration, and antihistamine use
“Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key inclusion criteria were moderate‐to‐severe CSU, defined as a weekly urticaria activity score (UAS7) of ≥ 16 (disease activity categories: 0, symptom free; 1–6, well‐controlled; 7–15, mild; 16–27, moderate; and 28–42, severe urticaria [11]); a weekly Hives Severity Score (HSS7) ≥ 8 (range: 0–21; higher values indicate greater severity) during the 7 days prior to randomization (Day 1); an in‐clinic UAS ≥ 4 on ≥ 1 screening visit days; antihistamine for treatment of CSU for at least 3 consecutive days immediately prior to the initial screening visit and were expected to use the antihistamines throughout the study period beginning at screening; CSU diagnosis for ≥ 6 months; and presence of itch and hives for ≥ 6 consecutive weeks at any time prior to enrollment despite concurrent use of antihistamine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients met defined hematology and chemistry criteria; had no other comorbidities that would introduce additional risk factors or interfere with study procedures; had no history of anaphylaxis; and had no known HIV, hepatitis B, or hepatitis C infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria: recent biologics, prior barzolvolimab, immunosuppressives, oral doxepin, and other itching skin disease
“Key exclusion criteria were receipt of prior biologic therapy (e.g., omalizumab, dupilumab, and ligelizumab) within the past 3 months or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half‐lives; treatment with doxepin (oral) within 4 weeks prior to study treatment; and any other skin disease associated with chronic itching that might confound study evaluations and results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior biologic treatment permitted with washout
Registry criteria: blood counts, contraception for 150 days, live vaccines, pregnancy, and anaphylaxis
Treatment
Intravenous infusion every 4 or 8 weeks as add-on to antihistamines
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry arms: CDX-0159 or normal saline every 4 to 8 weeks
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Registry primary outcome: incidence and severity of adverse events to Day 169
Safety assessments
“Safety was assessed by the incidence and severity of treatment‐emergent adverse events (TEAEs) and serious AEs (SAEs), dose‐limiting toxicities, clinical laboratory tests, vital sign measurements, 12‐lead electrocardiograms, and physical examinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale: first multiple-dose study after single-dose studies
“We report the effect of multiple ascending doses (MAD) of barzolvolimab on safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and clinical activity in CSU patients whose disease is inadequately controlled by antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry secondary outcomes: pharmacokinetics, UAS7, HSS7, ISS7, UCT, stem cell factor, tryptase, and immunogenicity
Weekly urticaria activity score (UAS7): components, range 0 to 42, and disease activity categories
Urticaria Control Test (UCT): range 0 to 16, complete control at 16, well controlled at 12 or more
Assessment ranges for UAS7, AAS7, UCT, and DLQI
Physician Global Assessment (PhysGA): range 0 to 3
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment: approximately 40 participants in four cohorts
Participants by cohort
“0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All barzolvolimab (N = 35)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pooled placebo (N = 10)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interim analysis population, May 2022 data cutoff
Analysis population, November 2022 data cutoff
Description of analysis sets
Safety population: all participants who received at least one dose
Analysis by dose with placebo pooled across cohorts
“Results were analyzed by dose and overall for patients who received barzolvolimab. The placebo group was pooled from each cohort. Baseline was defined as the last available measurement prior to study treatment administration. Change from baseline was calculated as the difference between postbaseline and baseline values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Safety was assessed separately by treatment group and as pooled active treatment. Analyses included the number and percentage of patients experiencing AEs, summarized by severity and relationship to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive pharmacokinetic, antidrug antibody, and pharmacodynamic analyses
“PK parameters were calculated using noncompartmental methods and summarized using descriptive statistics to compare exposure in single and multiple dose settings. The impact of antidrug antibodies (ADA) on drug levels and safety was evaluated by comparing the area under the concentration–time curve (AUC) and the incidence of AEs for ADA‐positive versus ADA‐negative patients in each treatment group, respectively. Summary statistics were descriptive and presented to evaluate PD changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis set and data included at the November 2022 data cutoff
Company responder analyses: participants with missing data excluded, Week 24 shown only where at least 50% had data
Results
Participant disposition
Completion of the 12-week treatment period
“Overall, 42 patients (93.3%) completed treatment (Figure S2). Three patients did not complete the treatment period: one in the barzolvolimab 4.5‐mg/kg group because of low white blood count (WBC), and two in the placebo group who sought alternate treatment for CSU because of symptom severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Doses not received and follow-up discontinuation, November 2022 data cutoff
Baseline characteristics
Demographics and baseline disease characteristics by cohort
Disease severity, prior omalizumab and biologic use, and angioedema history
“Patients had high mean (range) baseline CSU activity, with UAS7 = 29.6 (16.3–42.0) for barzolvolimab‐treated, UAS7 = 35.8 (19.0–42.0) for placebo‐treated, and 44% prior omalizumab use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority had an inadequate response to omalizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no notable differences between the barzolvolimab and placebo groups in the demographic or clinical characteristics at baseline (Table 1). Most patients had severe disease per UAS7. A total of 44% of patients had prior use of biologics. The percentage of patients with a history of angioedema was similar between placebo (50%) and across the barzolvolimab groups (60%), with mean baseline angioedema activity score over 7 days (AAS7) of 26.6 and 26.0, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Race, ISS7, HSS7, and total IgE at the November 2022 data cutoff
| Characteristic | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
|---|---|---|---|---|---|---|
| Race, White, n (%) | “6 (67)” | “7 (88)” | “9 (100)” | “7 (78)” | “29 (83)” | “7 (70)” |
| Race, African American, n (%) | “3 (33)” | “1 (13)” | “0 (0)” | “1 (11)” | “5 (14)” | “3 (30)” |
| Race, Other, n (%) | “0 (0)” | “0 (0)” | “0 (0)” | “1 (11)” | “1 (3)” | “0 (0)” |
| Prior angioedema, n (%) | “5 (56)” | “5 (63)” | “5 (56)” | “6 (67)” | “21 (60)” | “5 (50)” |
| ISS7, mean (range) | “15.7 (11.0 - 21.0)” | “15.5 (12.0 - 21.0)” | “14.6 (1.2 - 21.0)” | “15.4 (10.5 -19.0)” | “15.3 (1.2 - 21.0)” | “19.3 (12.0 - 21.0)” |
| HSS7, mean (range) | “15.4 (8.0 - 21.0)” | “14.0 (8.0 - 21.0)” | “14.8 (8.0 - 21.0)” | “12.4 (7.0 -19.0)” | “14.1 (7.0 - 21.0)” | “16.5 (7.0 - 21.0)” |
| UAS7, mean (range) | “31.1 (20.0 - 39.0)” | “29.4 (20.0 - 40.6)” | “29.4 (16.3 - 42.0)” | “27.8 (17.5 - 38.0)” | “29.4 (16.3 - 42.0)” | “35.8 (19.0 - 42.0)” |
| Total IgE, kU/L, mean (range) | “80 (2 - 239)” | “161 (13 - 328)” | “337 (4 - 1371)” | “88 (2 - 307)” | “165 (2 - 1371)” | “161 (5 - 409)” |
Baseline DLQI and PhysGA by cohort
| Characteristic | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
|---|---|---|---|---|---|---|
| DLQI, mean (range) | “13.2 (7-24)” | “15.1 (5-24)” | “7.8 (1-15)” | “9.7 (1-16)” | “11.3 (1-24)” | “13.5 (1-26)” |
| PhysGA, mean (range) | “1.9 (1-3)” | “2.3 (1-3)” | “2.7 (2-3)” | “2.1 (1-3)” | “2.2 (1-3)” | “2.1 (1-3)” |
Prior omalizumab use in interim company reports, May 2022 and November 2022 data cutoffs
Efficacy results
Week 12 UAS7 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6), all barzolvolimab doses versus placebo
“UAS7 response to barzolvolimab was greater than placebo: 71.4% of barzolvolimab‐treated patients had a well‐controlled response (UAS7 ≤ 6) by Week 12, compared with 30.0% of placebo‐treated patients (Figure 1C), and 57.1% of barzolvolimab‐treated patients had a complete response (UAS7 = 0) by Week 12 compared with 20% of placebo‐treated patients (Figure 1D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 12 UCT well-controlled disease (UCT ≥ 12) and complete response (UCT = 16), all barzolvolimab doses
UAS7, HSS7, ISS7, and UCT change from baseline from Week 1 through Week 24
“Urticaria symptoms measured by change from baseline in UAS7 improved by Week 1 (Figure 1A) for all barzolvolimab dose levels compared with placebo. Sustained improvement of UAS7 scores through Week 24 was seen for the groups ≥ 1.5 mg/kg. HSS7 and ISS7, the two components of UAS7 score, showed comparable improvement in each urticaria symptom measurement by Week 1 and sustained improvement of scores through Week 24 for the ≥ 1.5‐mg/kg groups (Figure S4). Sustained improvement was also observed by change from baseline in UCT (Figure 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Week 24 urticaria-free status (UAS7 = 0) at doses of 1.5 mg/kg or more, 16 weeks after the last dose
Transient response at the lowest dose (0.5 mg/kg)
Prior omalizumab subgroup: Week 12 UAS7 = 0 and UAS7 ≤ 6, pooled doses of 1.5 mg/kg or more
“A subgroup analysis of patients who had previously received omalizumab had a similar response profile (UAS7 and UCT) to those who were naive to omalizumab (Figure 3); the majority of experienced patients had discontinued prior omalizumab because of a lack of symptom control. Doses ≥ 1.5 mg/kg were pooled in barzolvolimab‐treated patients, and a complete response (UAS7 = 0) and well‐controlled response (UAS7 ≤ 6) by Week 12 were observed in 53.8% and 84.6% of barzolvolimab‐treated patients with prior omalizumab treatment, respectively, which is similar to the overall group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Authors' comparison with omalizumab registrational trials at Week 12
“A total of 71% of barzolvolimab‐treated patients across doses achieved a well‐controlled (UAS7 ≤ 6) response, and 57% of the patients achieved a complete response (UAS7 = 0) during the first 12 weeks (compared with 36% of participants treated with omalizumab 300 mg Q4W in registrational trials at 12 weeks [12]); this was sustained through Week 24.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled doses of 1.5 mg/kg or more: UAS7 = 0 and UAS7 ≤ 6 at Weeks 12 and 24
“56% of patients at Week 12” (opens the source at this quote in a new tab)
“55% of patients at Week 24” (opens the source at this quote in a new tab)
“Well controlled Urticaria at doses ≥ 1.5 mg/kg:” (opens the source at this quote in a new tab)
“64% of patients at Week 12” (opens the source at this quote in a new tab)
“60% of patients at Week 24” (opens the source at this quote in a new tab)
“Well Controlled Urticaria UAS7 ≤ 6” (opens the source at this quote in a new tab)
Week 12 UAS7 and UCT by cohort, November 2022 data cutoff
Pooled doses of 1.5 mg/kg or more: UAS7 = 0 at Weeks 12 and 20, November 2022 data cutoff
Week 24 UAS7 and UCT by cohort, complete 24-week data
Week 24 maintenance of a Week 12 complete response (UAS7 = 0), doses of 1.5 mg/kg or more
Interim Week 8 and Week 12 UAS7 and UCT results, May 2022 data cutoff
Angioedema: AAS7 improvement and angioedema-free participants (AAS7 = 0) at Weeks 12 and 24
Physician Global Assessment (PhysGA) from Week 1 through Week 24
“Physician Global Assessment (PhysGA) showed decreases starting at Week 1 (mean baseline score for pooled barzolvolimab group = 2.2 vs. 0.6 [Week 1]), which were sustained through Week 24 (Week 24 = 0.8 [1.5 mg/kg], 0.4 [3.0 mg/kg], and 0.6 [4.5 mg/kg]; Figure S6B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics: exposure through 24 weeks and dose-linear Cmax and AUC
“Multiple doses of barzolvolimab resulted in prolonged exposure through 24 weeks in the ≥ 1.5‐mg/kg dose levels (Figure 2A). Maximum serum concentration (Cmax) and AUC increased in a linear fashion with increasing dose (Table S1). Increased clearance and lower volumes of distribution were observed in patients who received lower doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barzolvolimab levels accumulated through multiple dosing cycles at all dose levels, and exposure by Cmax and AUC increased linearly with dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics: serum tryptase suppression and plasma SCF increase
“Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B). Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation. Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
DLQI through Week 24 at doses of 1.5 mg/kg or more
“Decreases in the Dermatology Life Quality Index (DLQI) mean scores for the ≥ 1.5‐mg/kg barzolvolimab groups were sustained through Week 24 (baseline score = 11.3 in pooled barzolvolimab group vs. Week 24 mean scores = 1.3 [1.5 mg/kg], 3.2 [3.0 mg/kg], and 2.0 [4.5 mg/kg]; Figure S6A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The increased symptom control observed with barzolvolimab was reflected in the quality of life measurements, which showed profound improvement between Weeks 1 and 4 that was sustained through Week 24.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DLQI decrease within 4 weeks in all barzolvolimab groups
Safety results
Treatment-emergent adverse events through 24 weeks: incidence, infusion-related events, interruptions, and discontinuations
“Overall, 30 barzolvolimab‐treated patients (86%) and 6 placebo‐treated patients (60%) experienced a TEAE. In the 1.5‐mg/kg group, two barzolvolimab‐treated patients (6%) experienced infusion‐related TEAEs. One patient (3%) in the 3.0‐mg/kg group experienced a TEAE that led to drug interruption. No patients experienced a dose‐limiting toxicity or any TEAE that led to treatment discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most AEs were mild or moderate in severity and resolved while on study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TEAEs in at least 10% of barzolvolimab-treated participants by cohort at 24 weeks
Hair color changes: locations and resolution
“Hair color change was the most common event, experienced by nine barzolvolimab‐treated patients (26%; Table 2); hair color changes occurred in different locations: scalp, beard, and body hair; and seven patients had this TEAE resolve by the end of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infections and their relation to neutrophil decreases
“A total of 40% of barzolvolimab‐treated patients and 20% of placebo‐treated patients experienced an infection AE. The infections that were reported by > 10% of barzolvolimab‐treated patients were COVID‐19 (14%), nasopharyngitis (11%), and UTI (11%), and were not correlated with neutrophil decreases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse event: grade 4 salmonella gastroenteritis assessed as unrelated
“One SAE of Grade 4 salmonella gastroenteritis in a 59‐year‐old Black woman (1.5‐mg/kg group) was assessed by the investigator as unrelated to study treatment; she was treated with Levaquin, was discharged, and completed the study as planned.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hematologic decreases after the first dose and grade 3 shifts
“Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: antidrug antibodies in 57% without apparent effect on exposure or safety
“Fifty‐seven percent (20/35) of patients were ADA positive, and the proportion of patients who experienced drug‐related AEs was similar in ADA‐positive and ADA‐negative patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment‐emergent ADA were observed in 57% of barzolvolimab‐treated patients, without apparent impact on exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity: antidrug antibodies in 51%, November 2022 data cutoff
KIT-mediated adverse events and expected recovery after drug clearance
“The observed AEs in barzolvolimab‐treated patients reflect KIT‐mediated toxicities and were reversible, consistent with the expected effects of KIT inhibition. The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in at least 10% of barzolvolimab-treated participants, November 2022 data cutoff
| AE, n (%) | 0.5 mg/kg Q4W (N= 9) | 1.5 mg/kg Q4W (N= 8) | 3.0 mg/kg Q8W (N= 9) | 4.5 mg/kg Q8W (N= 9) | All barzolvolimab (N= 35) | Pooled placebo (N= 10) |
|---|---|---|---|---|---|---|
| Any AE | “8 (89)” | “7 (88)” | “9 (100)” | “6 (67)” | “30 (86)” | “5 (50)” |
| Hair color changes | “0 (0)” | “1 (13)” | “3 (33)” | “4 (44)” | “8 (23)” | “0 (0)” |
| COVID-19 | “0 (0)” | “1 (13)” | “2 (22)” | “2 (22)” | “5 (14)” | “0 (0)” |
| Headache | “2 (22)” | “0 (0)” | “2 (22)” | “1(11)” | “5 (14)” | “1 (10)” |
| Neutropenia | “2 (22)” | “2 (25)” | “1 (11)” | “0 (0)” | “5 (14)” | “0 (0)” |
| Urinary tract infection, cystitis, and bacteriuria | “1 (11)” | “2 (25)” | “2 (22)” | “0 (0)” | “5 (14)” | “0 (0)” |
Urinary tract infection grouped with cystitis and bacteriuria in a later congress poster
Interim safety, May 2022 data cutoff
Neutrophil decreases reported as adverse events and hematologic recovery, November 2022 data cutoff
Study limitations
Summary
- Author-stated limitations: “This study was limited by the small sample size and variation in drugs used for background urticaria treatment”, with participants required to be on a stable regimen before barzolvolimab administration.
- Sample size and design: 45 participants were randomized, 35 to barzolvolimab in four sequentially enrolled cohorts of 8 or 9 and 10 to placebo pooled from each cohort (4:1 within cohorts). Analyses of pharmacokinetics, antidrug antibodies, and pharmacodynamics were descriptive.
- Applicability of dosing: barzolvolimab was given as a 60-minute intravenous infusion at 0.5 to 4.5 mg/kg every 4 or 8 weeks for 12 weeks; the phase 3 trials use subcutaneous 150 mg every 4 weeks or 300 mg every 8 weeks after a loading dose. The registry title calls the study phase 1, and the publication calls it phase 1b.
- Follow-up and missing data: follow-up lasted 12 weeks or until symptoms resumed. Company responder analyses excluded participants with missing data at a timepoint and showed Week 24 only for dose levels with at least 50% of participants with data; data for 0.5 mg/kg and placebo were included only through week 12 because most of those participants had significant symptoms ahead of week 24 and discontinued follow up. Two placebo participants did not complete treatment because they sought alternate treatment for symptom severity.
- Baseline differences: mean UAS7 was 35.8 in the placebo group and 29.6 in the barzolvolimab group, and prior omalizumab was recorded in 6 (60%) placebo and 13 (37%) barzolvolimab participants in Table 1; the publication states there were no notable differences between groups at baseline.
- Antidrug antibodies, by document: 57% (20/35) in the publication; 51% in the November 2022 data cutoff poster.
- Hair color changes, by document: 9 (26%) in the publication; 8 (23%) in the November 2022 poster.
- Any adverse event with placebo, by document: 6 (60%) in the publication; 5 (50%) in the November 2022 poster.
- Urinary tract infection, by document: 4 (11%) in the publication; 5 (14%) in the November 2022 poster and 7 (20%) in the EADV 2023 poster, both of which group urinary tract infection, cystitis, and bacteriuria.
- Prior omalizumab, by document: 44% in the publication's summary statement; 37% of treated participants in the company release reporting the November 2022 data cutoff; 42% of barzolvolimab-treated participants at the May 2022 data cutoff.
- Baseline AAS7, by document: 26.6 (placebo) and 26.0 (barzolvolimab) in the publication text; 53.2 (placebo) and 34 (barzolvolimab) among participants AAS7 positive at baseline in Table 1.
- Disposition, by document: three participants did not complete the treatment period (publication); two did not receive all doses of study treatment (company release reporting the November 2022 data cutoff).
- The omalizumab-experienced subgroup at pooled doses of 1.5 mg/kg or more is n=9 in the EAACI 2023 poster.
- Sponsor role: the trial was designed and sponsored by Celldex Therapeutics, data were analyzed by the sponsor, and the first draft of the manuscript was written by a medical writer paid by the sponsor.
- External comparison: the publication sets the 57% Week 12 complete response beside 36% for omalizumab 300 mg Q4W in registrational trials at 12 weeks.